Effects of Thoracolumbar Fascia Myofascial Release in Chronic Low Back Pain

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorUniversity of Health Sciences Lahore

About this trial

The thoracolumbar fascia (TLF) is thickened and stiffer in individuals with chronic non-specific low back pain (CNSLBP) and may contribute to pain persistence. Myofascial release (MFR) has been shown to reduce TLF stiffness acutely; however, its longer-term effects on fascial morphology and pain self-efficacy remain unclear. This randomized controlled trial will investigate the effects of a standardized 6-week MFR program targeting the thoracolumbar fascia compared with sham MFR in adults with CNSLBP. A total of 65 participants aged 18-60 years with CNSLBP will be randomized in a 1:1 ratio to either standardized MFR or sham MFR. The intervention will consist of 18 treatment sessions delivered over 6 weeks. Primary outcomes include thoracolumbar fascia thickness measured by B-mode ultrasound, thoracolumbar fascia stiffness measured by shear-wave elastography, and pain self-efficacy measured using the Pain Self-Efficacy Questionnaire (PSEQ). Secondary outcomes include pain intensity, functional disability, lumbar flexion range of motion, and patient global impression of change. Outcomes will be assessed at baseline and after completion of the 6-week intervention period.

Eligibility criteria

Qualifiers

Adults aged 18-60 years

Non-specific low back pain duration > 12 weeks

Average pain intensity NRS ≥ 3 over the past week

Able to provide written informed consent

Disqualifiers

Specific spinal pathology (fracture, disc herniation with neurological deficit, spinal stenosis, inflammatory arthropathy, malignancy)

Previous lumbar surgery

Current pregnancy

Severe psychiatric disorder or active psychosis

Trial design

Treatments tested in this trial

  • Myofascial Release of Thoracolumbar Fascia
  • Sham Myofascial Release

Treatment groups

65 Participants
are divided into 2 treatment groups